GIUV2018-426
Identification of molecular mechanisms, new pharmacological targets and active molecules in cardiovascular pathologies such as hypertension, human heart failure and obesity. Cardiovascular diseases continue to be the leading cause of death in our environment and research into the mechanisms that generate them, as well as the possibilities of pharmacological action to modulate these mechanisms, are priority lines of research at national and European level. Our group focuses on three pathologies, obesity, hypertension and heart failure, and carries out translational research dedicated to the identification of new pharmacological targets and active molecules in these pathologies, working in both animal and human models. In addition, from a healthcare approach, its activity also focuses on research into the rational use of drugs in the field of community pharmacy, pharmacovigilance, public health, etc. The group's research focuses on identifying the changes that occur in obesity, hypertension and heart failure at the level of molecular mechanisms related to adrenergic regulation (via alpha1 or beta receptors) of the heart, vessels or adipose tissue, and their interrelation with the...Identification of molecular mechanisms, new pharmacological targets and active molecules in cardiovascular pathologies such as hypertension, human heart failure and obesity. Cardiovascular diseases continue to be the leading cause of death in our environment and research into the mechanisms that generate them, as well as the possibilities of pharmacological action to modulate these mechanisms, are priority lines of research at national and European level. Our group focuses on three pathologies, obesity, hypertension and heart failure, and carries out translational research dedicated to the identification of new pharmacological targets and active molecules in these pathologies, working in both animal and human models. In addition, from a healthcare approach, its activity also focuses on research into the rational use of drugs in the field of community pharmacy, pharmacovigilance, public health, etc. The group's research focuses on identifying the changes that occur in obesity, hypertension and heart failure at the level of molecular mechanisms related to adrenergic regulation (via alpha1 or beta receptors) of the heart, vessels or adipose tissue, and their interrelation with the nitric oxide (NO) pathway. In this direction, the role of neurotrophin-3, which regulates neuronal growth during embryonic development, is also being analysed. The aim is to find new pharmacological targets to normalise altered cardiovascular function through its regulation. Knowledge of new targets will also allow the testing of molecules active on them as possible therapeutic tools. Thus, and within a translational research framework, the lines described below are being developed:
Characterisation of the pathways mediated by alpha1 and beta adrenoceptors as possible pharmacological targets in obesity and cardiovascular pathology.
Gene and protein expression of neurotrophin-3 and its receptor TrkC.
Characterisation of the neurotrophin-3 pathway as a new pharmacological target in animal models of obesity and cardiovascular pathology.
Characterisation of the NO pathway and the role of constitutive NO synthases as possible pharmacological targets.
Relationship between the NO pathway and adrenergic or TrkC receptor-mediated transduction pathways.
Characterisation of the angiogenic process in human/murine vessels and its regulation by adrenoceptors, NT-3 and NO.
Consequences of hypoxia/ischemia on these pathways.
Identification of the changes observed in animal models and in obese, hypertensive, heart failure and heart transplant patients.
Identification of human biomarkers in these pathologies.
Search for molecules active on these pathways. To develop these lines, collaborations have been established, consolidated in projects at national and international level, with groups of researchers from other universities, private companies or the CSIC, and with clinical groups from the Hospital La Fe, the Hospital de La Ribera-Alzira and the INCLIVA Health Research Institute.
[Read more][Hide]
[Read more][Hide]
- Identificacion de los mecanismos moleculares de obesidad, hipertension e insuficiencia cardiaca humanas; determinacion de biomarcadores humanos.
- Regulacion transcripcional, señalizacion y expresion de adrenoceptores y NT-3 en obesidad, hipertension e insuficiencia cardiaca humanas
- Caracterizacion del proceso angiogenico en vasos humanos/murinos y su papel en la obesidad, hipertension e insuficiencia cardiaca humanas
- Caracterizacion de adrenoceptores y sus vias de transduccion, incluida la via del Oxido Nitrico, como dianas farmacologicas.
- Caracterizacion de la neurotrofina-3 como nueva diana farmacologica en obesidad, hipertension e insuficiencia cardiaca
- Cardiovascular pharmacology.Identification of molecular mechanisms, new pharmacological targets and active molecules in cardiovascular pathologies and obesity.
| Name | Nature of participation | Entity | Description |
|---|---|---|---|
| MARIA PILAR D'OCON NAVAZA | Director | Universitat de València | |
| Research team | |||
| MARIA DOLORES IVORRA INSA | Member | Universitat de València | |
| MARIA ANTONIA NOGUERA ROMERO | Member | Universitat de València | |
- -
- ERI Biotechnology and Biomedicine (BIOTECMED)
- Farmacología, cardiovascular, obesidad, hipertensión, insuficiencia cardiaca, neurotrofinas, adrenoceptores
